Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)

A Randomized, Parallel, Double Blind Study of Losartan Versus Amlodipine in Patients With Mild to Moderate Hypertension and Chronic Nondiabetic Proteinuric Nephropathy: Evaluation of the Effect on Proteinuria and on the Plasmatic Levels of Growth Factors (TGFß and VEGF)

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00140985

Enrollment

Registered

2005-09-01

Start date

2000-02-29

Completion date

2002-01-31

Last updated

2022-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Disorder

Brief summary

Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric Renal Diseases.

Interventions

DRUGMK0954, losartan potassium/Duration of Treatment: 20 weeks

DRUGComparator: amlodipine / Duration of Treatment: 20 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Males or females at least 18 years of age with non-diabetic proteinuric renal diseases

Design outcomes

Primary

Measure	Time frame
24h proteinuria	—

Secondary

Measure	Time frame
Changes in the plasma and urinary levels of TGF-beta	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026